...
bmy-img

Bristol-Myers Squibb Company, Common Stock

BMY

NYQ

$43.94

-$0.7

(-1.57%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$89.07B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
NM
Volume info-icon
This is the total number of shares traded during the most recent trading day.
17.47M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
13.36M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
5.35%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$44.34 L
$66.25 H
$43.94

About Bristol-Myers Squibb Company, Common Stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameBMYSectorS&P500
1-Week Return-10.31%-0.62%0.86%
1-Month Return-16.11%-4.12%-2.34%
3-Month Return-10%0.26%4.25%
6-Month Return-12.26%14.32%23.68%
1-Year Return-33%6.35%24.66%
3-Year Return-21.88%21.28%28%
5-Year Return11.89%71.51%88.59%
10-Year Return18.34%183.91%226.28%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue26.14B42.52B46.38B46.16B45.01B[{"date":"2019-12-31","value":56.37,"profit":true},{"date":"2020-12-31","value":91.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.51,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}]
Cost of Revenue8.08B11.77B9.94B10.14B10.69B[{"date":"2019-12-31","value":68.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.43,"profit":true},{"date":"2022-12-31","value":86.1,"profit":true},{"date":"2023-12-31","value":90.83,"profit":true}]
Gross Profit18.07B30.75B36.45B36.02B34.31B[{"date":"2019-12-31","value":49.57,"profit":true},{"date":"2020-12-31","value":84.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.84,"profit":true},{"date":"2023-12-31","value":94.15,"profit":true}]
Gross Margin69.10%72.31%78.57%78.04%76.24%[{"date":"2019-12-31","value":87.95,"profit":true},{"date":"2020-12-31","value":92.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.32,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}]
Operating Expenses12.15B28.57B27.91B26.92B26.12B[{"date":"2019-12-31","value":42.54,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.69,"profit":true},{"date":"2022-12-31","value":94.22,"profit":true},{"date":"2023-12-31","value":91.42,"profit":true}]
Operating Income5.46B5.13B10.16B10.33B17.24B[{"date":"2019-12-31","value":31.69,"profit":true},{"date":"2020-12-31","value":29.74,"profit":true},{"date":"2021-12-31","value":58.92,"profit":true},{"date":"2022-12-31","value":59.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(1.15B)(13.42B)(3.40B)(3.85B)267.00M[{"date":"2019-12-31","value":-428.84,"profit":false},{"date":"2020-12-31","value":-5025.84,"profit":false},{"date":"2021-12-31","value":-1271.54,"profit":false},{"date":"2022-12-31","value":-1440.82,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income4.97B(6.87B)8.10B7.71B8.44B[{"date":"2019-12-31","value":58.95,"profit":true},{"date":"2020-12-31","value":-81.41,"profit":false},{"date":"2021-12-31","value":95.95,"profit":true},{"date":"2022-12-31","value":91.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes1.51B2.12B1.08B1.37B400.00M[{"date":"2019-12-31","value":71.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.04,"profit":true},{"date":"2022-12-31","value":64.41,"profit":true},{"date":"2023-12-31","value":18.83,"profit":true}]
Income After Taxes3.46B(8.99B)7.01B6.34B8.04B[{"date":"2019-12-31","value":43.03,"profit":true},{"date":"2020-12-31","value":-111.88,"profit":false},{"date":"2021-12-31","value":87.24,"profit":true},{"date":"2022-12-31","value":78.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations6.49B(8.99B)7.01B6.34B8.30B[{"date":"2019-12-31","value":78.16,"profit":true},{"date":"2020-12-31","value":-108.33,"profit":false},{"date":"2021-12-31","value":84.48,"profit":true},{"date":"2022-12-31","value":76.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income3.44B(8.99B)6.99B6.33B8.03B[{"date":"2019-12-31","value":42.85,"profit":true},{"date":"2020-12-31","value":-112.09,"profit":false},{"date":"2021-12-31","value":87.15,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)4.676.447.507.807.50[{"date":"2019-12-31","value":59.87,"profit":true},{"date":"2020-12-31","value":82.56,"profit":true},{"date":"2021-12-31","value":96.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.15,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BMY
Cash Ratio 0.37
Current Ratio 1.11
Quick Ratio 0.99

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BMY
ROA (LTM) 5.39%
ROE (LTM) -25.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BMY
Debt Ratio Lower is generally better. Negative is bad. 0.83
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.17
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 6.01

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BMY
Trailing PE NM
Forward PE 6.93
P/S (TTM) 2.17
P/B 3.32
Price/FCF 35
EV/R 2.82
EV/Ebitda 6.56
PEG 0.08

News

Judge tosses Medicare drug negotiation challenges from Bristol Myers Squibb, Johnson & Johnson

A federal judge on Monday threw out legal challenges to the Medicare negotiation program that had been brought by Bristol Myers Squibb and Johnson & Johnson, finding that their claims of unconstitutionality do not hold up. In their two separate lawsuits, both Bristol Myers Squibb and Johnson & Johnson allege that the Medicare negotiation program…

30 Apr, 2024 a 5:18 pm The Hill

Fuel Africa 2024: Futurize and AstraZeneca Unveil Groundbreaking HealthTech Innovations

Today, Fuel Africa 2024, a groundbreaking initiative hosted by Futurize, has successfully concluded, marking a significant milestone in integrating healthcare technology innovations with climate change solutions across the African continent. Through the collaborative efforts of AstraZeneca through the A.Catalyst Network, and co-funded by Bristol Myers Squibb, the initiative aims to tackle immediate healthcare challenges while […] The post Fuel Africa 2024: Futurize and AstraZeneca Unveil Groundbreaking HealthTech Innovations appeared first on Tech | Business | Economy .

30 Apr, 2024 a 2:11 pm TechEconomy

Fuel Africa 2024: Futurize and AstraZeneca Unveil Groundbreaking Innovations for Health Tech and Environmental Sustainability

.… In partnership with AstraZeneca through the A. Catalyst Network and co-funded by Bristol Myers Squibb, the program tackles immediate healthcare needs and long-term resilience strategies. Today, Fuel Africa 2024, a groundbreaking initiative hosted by Futurize, has successfully concluded, marking a significant milestone in integrating healthcare technology innovations with climate change solutions across the African […] The post Fuel Africa 2024: Futurize and AstraZeneca Unveil Groundbreaking Innovations for Health Tech and Environmental Sustainability appeared first on ITPulse.com.ng .

30 Apr, 2024 a 1:31 pm ITPulse

Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb

Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion. Under the terms of the agreement, Scenic Biotech will be entitled Jetzt den vollständigen Artikel lesen

30 Apr, 2024 a 9:00 am Wallstreet:Online

Japan''s Ono Pharma says $2.4 billion Deciphera purchase ''first step'' for global expansion

… billion takeover of Deciphera Pharmaceuticals is a " … Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which … U.S. by partner Bristol-Myers Squibb . The drug expected to … million in 2023. Ono Pharma expects Qinlock and Vimseltinib …

30 Apr, 2024 a 8:05 am EIN News Pharmaceuticals

J&J, Bristol Myers lose challenges to US drug price negotiation programme

NEW YORK, April 30 ― A US judge yesterday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law…

29 Apr, 2024 a 11:56 pm Malay Mail

Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations

The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.

29 Apr, 2024 a 10:22 pm CNBC

FAQs

What is Bristol-Myers Squibb Company share price today?

Bristol-Myers Squibb Company (BMY) share price today is $43.94

Can Indians buy Bristol-Myers Squibb Company shares?

Yes, Indians can buy shares of Bristol-Myers Squibb Company (BMY) on Vested. To buy Bristol-Myers Squibb Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BMY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Bristol-Myers Squibb Company be purchased?

Yes, you can purchase fractional shares of Bristol-Myers Squibb Company (BMY) via the Vested app. You can start investing in Bristol-Myers Squibb Company (BMY) with a minimum investment of $1.

How to invest in Bristol-Myers Squibb Company shares from India?

You can invest in shares of Bristol-Myers Squibb Company (BMY) via Vested in three simple steps:

  • Click on Sign Up or Invest in BMY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Bristol-Myers Squibb Company shares
What is Bristol-Myers Squibb Company 52-week high and low stock price?

The 52-week high price of Bristol-Myers Squibb Company (BMY) is $66.25. The 52-week low price of Bristol-Myers Squibb Company (BMY) is $44.34.

What is Bristol-Myers Squibb Company price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Bristol-Myers Squibb Company (BMY) is NM

What is Bristol-Myers Squibb Company price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Bristol-Myers Squibb Company (BMY) is 3.32

What is Bristol-Myers Squibb Company dividend yield?

The dividend yield of Bristol-Myers Squibb Company (BMY) is 5.35%

What is the Market Cap of Bristol-Myers Squibb Company?

The market capitalization of Bristol-Myers Squibb Company (BMY) is $89.07B

What is Bristol-Myers Squibb Company’s stock symbol?

The stock symbol (or ticker) of Bristol-Myers Squibb Company is BMY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top